Skip to Main content Skip to Navigation
Journal articles

Médicaments et risque de cancer : l’exemple du traitement hormonal de la ménopause

Abstract : Estrogen-progestagen menopausal hormone therapy (MHT), indicated for the treatment of troublesome climacteric symptoms, is recognized as carcinogenic to humans. We present the available epidemiologic evidence concerning its link with the risks of breast, ovarian, endometrial and colorectal cancers.While results on cancers other than breast cancer are still imprecise or even contradictory, there is a clear increase in breast cancer risk associated with the use of estrogen-progestagen MHT. Attempts to play down in the public opinion the risk of breast cancer associated with these treatments evoke a better prognosis of tumors induced by MHT, the fact that MHT would only accelerate the presentation of pre-existing breast tumors that would otherwise have appeared latter, or that MHT would be devoid of risks when initiated close to menopause onset. We show that these assertions are not supported by the available epidemiological evidence.
Complete list of metadata

Cited literature [31 references]  Display  Hide  Download
Contributor : Agnès Fournier Connect in order to contact the contributor
Submitted on : Wednesday, November 26, 2014 - 11:29:31 AM
Last modification on : Sunday, June 26, 2022 - 12:02:19 PM
Long-term archiving on: : Friday, February 27, 2015 - 11:16:17 AM


Médicaments et risque de canc...
Files produced by the author(s)


  • HAL Id : inserm-01087488, version 1
  • PUBMED : 24298831



Agnès Fournier, Catherine Hill. Médicaments et risque de cancer : l’exemple du traitement hormonal de la ménopause. Revue du Praticien (La), J B Bailliere et Fils, 2013, 63 (8), pp.1117-21. ⟨inserm-01087488⟩



Record views


Files downloads